Society of Infectious Diseases Pharmacists | Strategic Alliance Partners

Empiric anti-MRSA therapy is an area of opportunity for antimicrobial stewardship in the treatment of CAP.

Guidelines, updated in nearly real time, recommend use of remdesivir, dexamethasone.

Baloxavir marboxil and oseltamivir are options for treating uncomplicated influenza.

Institutions should consider optimal targets, testing volumes, and notification and reporting practices when making their choice.

Antiretroviral therapy’s limitations lead to new efforts to treat the virus by neutralizing antibodies.

Cefiderocol and IV fosfomycin are exciting new options, and further clinical outcomes data will help define their roles.

What are the advantages and disadvantages of linezolid versus daptomycin for vancomycin-resistant enterococcus bacteremia?

The easiest way to avoid misdiagnosis, inappropriate treatment, and potential loss of reimbursement is to prevent unsuitable testing.

Antimicrobial resistance continues to pose a significant health threat, necessitating new antibiotics with novel mechanisms to treat these complicated infections. However, between 2010 and 2018, newly approved antibiotics were primarily derived from previously established drug classes. This past summer, the FDA approved 2 new antibiotics.

Eravacycline, Omadacycline, Plazomicin, and a Rifamycin Add to the Armamentarium for Treating Resistant Infections

Pharmacy Times has announced the addition of the Society of Infectious Diseases Pharmacists (SIDP) to its Strategic Alliance Partnership (SAP) program.

Expansion to adolescents, flexible dosing strategies, innovative delivery models, and long-acting antiretrovirals all help the strategy.

Pharmacists who have patients receiving the antibiotic should familiarize themselves with the methods for optimizing this agent.

The newly FDA-approved drug blocks viral replication and RNA transcription via a cap-dependent endonuclease inhibitor.